Q-Line Biotech IPO

About Q-Line Biotech IPO

The Q-Line Biotech IPO opens on Thursday, May 21, 2026 and closes on Monday, May 25, 2026. The allotment of shares will take place on Tuesday, May 26, 2026. The credit of shares to the demat account will take place on Wednesday, May 27, 2026. The initiation of refunds will take place on Wednesday, May 27, 2026. The listing of shares will take place on Friday, May 29, 2026.

The offer consists of a fresh issue component. The fresh issue will include up to 0.63 crore shares of ₹214.48 crores. The total number of shares and aggregate amount are 62,53,200 shares aggregating up to ₹214 crores.

Q-Line Biotech IPO’s price band is set at ₹326 to ₹343 per share. The lot size for an application is 400 shares. The minimum amount of investment required by a retail investor is ₹2,74,400 (800 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (1,200 shares), amounting to ₹4,11,600.

Q-Line Biotech is a research-driven company engaged in developing and manufacturing a wide range of reagent formulations used across various IVD and diagnostic needs. They leverage their R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations/products. Furthermore, for certain classes of reagents, equipment and devices in their manufacturing business, the company has entered into technical collaboration with certain international companies.

Objectives of Q-Line Biotech IPO

• To meet working capital requirements.
  
• Repayment of certain borrowing availed by the company, in part or full.
  
• General corporate purposes.
  

Industry Outlook

As for India's healthcare sector, the IVD industry is poised for steady growth, fueled by technological innovations, growing geriatric populations, cost-efficient solutions, and increased adoption. The industry is moving towards automation enhancing accuracy and efficiency in disease detection.

Going forward, the diagnostic testing market is projected to maintain its steady expansion, reaching 297.80 crore USD in CY30, with each test type maintaining proportional growth. This underscores the crucial role of diagnostics in early disease detection, precision medicine, and the broader healthcare landscape.

About Q-Line Biotech

Q-Line Biotech is engaged in the business of developing, manufacturing and marketing of a diverse range of reagents (including kits and POC devices) & consumables and the manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company has supplied diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013, directly or through their distributors, majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of Q-Line in the IVD industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

Strengths of Q-Line Biotech

• Established manufacturing capabilities with a focus on R&D, reverse engineering and quality control.
  
• Diversified product portfolio with a focus on the IVD industry.
  
• Widespread distribution network with a presence across all four regions.
  
• Long-standing relationships with customers.
  
• Track record of healthy financial performance.
  

Risks of Q-Line Biotech

• Any disruption, stoppage, slowdown or shutdown in their manufacturing facilities or processes or research and development activities.
  
• Any delay, interruption or reduction in the supply of their raw materials and trade goods from their suppliers and manufacturers, or an increase in the costs of such raw materials and trade goods.
  
• Any loss of business in North India.
  
• Face pricing pressure from their competitors, local or state government.
  
• Exchange rate fluctuations.
  

Anchor Investor Bidding Date: Wednesday, May 20, 2026

The company, in consultation with the BRLMs, may consider participation by Anchor Investors, in accordance with the SEBI (ICDR) Regulations. The Anchor Investor Bidding date shall be one working day prior to the Bid/Issue opening date.

Registrar: Purva Sharegistry (India) Private Limited
Book Running Lead Managers:
Hem Securities Limited
Share India Capital Services Private Limited

Q-Line Biotech Business Model

The company earns its revenue through the following: Developing, manufacturing and marketing of a diverse range of reagents (including kits and POC devices) & consumables and the manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs.

Q-Line Biotech Growth Trajectory

(Restated Consolidated Data) Q-Line Biotech’s Total Income for FY25 was ₹322.584 crores, whereas in FY24 and FY23 it was ₹206.448 crores and ₹184.811 crores, respectively.

The Profit After Tax for FY25 was ₹28.131 crores, whereas in FY24 and FY23 it was ₹34.445 crores and ₹32.097 crores, respectively.

Their EBITDA for FY25 was ₹71.321 crores, whereas in FY24 and FY23 it was ₹37.625 crores and ₹32.977 crores, respectively.

Company Market Position

Q-Line Biotech maintains a comprehensive marketing and distribution infrastructure to support sales and service for its customers, complemented by their distributor network for efficient logistics and supply chain management. They prioritise building relationships with their customers and distributors for their business growth and market penetration. They cater mainly to the Northern region and sell a portion of their products to other regions across India and plan to expand into the international market.

As of 31 March 2025, the company’s Total Income, Profit After Tax, and EBITDA were ₹322.584 crores, ₹28.131 crores, and ₹71.321 crores, respectively.

How to apply for Q-Line Biotech IPO?

• Step 1: Log in to your Kotak Neo Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details. Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification. Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.